---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-122215"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2024-04-29T23:59:59+00:00"
generated_at: "2026-06-03T05:34:32.812899+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics names Thomas Leggett CFO; Stephen Tulipano resigns

## Summary
- Thomas Leggett appointed CFO effective May 7, 2024; previously CFO at Affinia Therapeutics and Black Diamond Therapeutics.
- Leggett receives $475,000 base salary, 40% bonus target, and option for 396,200 shares vesting over 4 years.
- Current CFO Stephen Tulipano resigns effective May 7; will serve as advisor through Dec 31, 2024.
- Tulipano retains equity vesting during transition period and up to $15,000 in outplacement services.
- Leggett holds B.A. from Columbia and M.B.A. from Wharton; also board member at Clover Biopharmaceuticals.

## SEC filing metadata
- accession: 0001193125-24-122215
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2024-04-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312524122215/0001193125-24-122215-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312524122215/d810575d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-122215
- JSON: https://secwatch.observer/filing/0001193125-24-122215.json
- Plain text: https://secwatch.observer/filing/0001193125-24-122215.txt

## Key facts
- Executive change
  Thomas Leggett was appointed as Chief Financial Officer at Stoke Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: appointed Thomas Leggett as the Chief Financial Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000119312524122215/0001193125-24-122215-index.htm
- Executive change
  Stephen Tulipano resigned as Chief Financial Officer at Stoke Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Resignation of Chief Financial Officer Effective as of the Appointment Date, the Company’s current Chief Financial Off
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000119312524122215/0001193125-24-122215-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.